Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge.
Journal
PLoS biology
ISSN: 1545-7885
Titre abrégé: PLoS Biol
Pays: United States
ID NLM: 101183755
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
12
05
2021
accepted:
17
10
2021
revised:
16
11
2021
pubmed:
5
11
2021
medline:
15
12
2021
entrez:
4
11
2021
Statut:
epublish
Résumé
The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has resulted in a pandemic causing significant damage to public health and the economy. Efforts to understand the mechanisms of Coronavirus Disease 2019 (COVID-19) have been hampered by the lack of robust mouse models. To overcome this barrier, we used a reverse genetic system to generate a mouse-adapted strain of SARS-CoV-2. Incorporating key mutations found in SARS-CoV-2 variants, this model recapitulates critical elements of human infection including viral replication in the lung, immune cell infiltration, and significant in vivo disease. Importantly, mouse adaptation of SARS-CoV-2 does not impair replication in human airway cells and maintains antigenicity similar to human SARS-CoV-2 strains. Coupled with the incorporation of mutations found in variants of concern, CMA3p20 offers several advantages over other mouse-adapted SARS-CoV-2 strains. Using this model, we demonstrate that SARS-CoV-2-infected mice are protected from lethal challenge with the original Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), suggesting immunity from heterologous Coronavirus (CoV) strains. Together, the results highlight the use of this mouse model for further study of SARS-CoV-2 infection and disease.
Identifiants
pubmed: 34735434
doi: 10.1371/journal.pbio.3001284
pii: PBIOLOGY-D-21-01241
pmc: PMC8594810
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3001284Subventions
Organisme : NIAID NIH HHS
ID : R21 AI145400
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI090023
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI153602
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001440
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007526
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI120942
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI147623
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI060549
Pays : United States
Commentaires et corrections
Type : UpdateOf
Déclaration de conflit d'intérêts
We have read the journal’s policy and the authors of this manuscript have the following competing interests: XX, P-YS, and VDM have filed a patent on the reverse genetic system and reporter SARS-CoV-2. Other authors declare no competing interests.
Références
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Science. 2020 May 29;368(6494):942-943
pubmed: 32467379
J Virol. 2015 Feb;89(4):1954-64
pubmed: 25428871
J Virol. 2020 Sep 15;94(19):
pubmed: 32699094
Viruses. 2020 Jan 24;12(2):
pubmed: 31991541
mBio. 2013 Apr 30;4(3):e00165-13
pubmed: 23631916
Nat Commun. 2020 Aug 13;11(1):4059
pubmed: 32792628
J Virol. 2011 Jan;85(1):217-30
pubmed: 20980507
PLoS Pathog. 2007 Jan;3(1):e5
pubmed: 17222058
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
J Microbiol Immunol Infect. 2021 Feb;54(1):12-16
pubmed: 32425996
Virus Res. 2008 Apr;133(1):45-62
pubmed: 17416434
Lancet. 2021 Apr 17;397(10283):1421-1423
pubmed: 33844964
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Immunol Res. 2014 Aug;59(1-3):118-28
pubmed: 24845462
Cell. 2020 Nov 12;183(4):1070-1085.e12
pubmed: 33031744
Nat Protoc. 2021 Mar;16(3):1761-1784
pubmed: 33514944
bioRxiv. 2021 Mar 09;:
pubmed: 33758836
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Expert Rev Vaccines. 2009 Jul;8(7):887-98
pubmed: 19538115
Elife. 2021 Sep 28;10:
pubmed: 34581669
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Nucleic Acids Res. 2014 Jan;42(2):e11
pubmed: 24137010
Science. 2020 Sep 25;369(6511):1603-1607
pubmed: 32732280
J Virol. 2019 Oct 29;93(22):
pubmed: 31462558
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
J Mol Biol. 2015 Aug 14;427(16):2610-6
pubmed: 26116762
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
Emerg Infect Dis. 2020 Jun;26(6):1266-1273
pubmed: 32160149
J Virol. 2007 Jan;81(2):813-21
pubmed: 17079315
medRxiv. 2021 Jan 20;:
pubmed: 33501468
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nucleic Acids Res. 2017 Jan 4;45(D1):D313-D319
pubmed: 27899672
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
J Cell Physiol. 2021 Oct;236(10):7045-7057
pubmed: 33755190
Nat Med. 2015 Dec;21(12):1508-13
pubmed: 26552008
J Virol. 2012 Jan;86(2):884-97
pubmed: 22072787
Genome Res. 2017 Mar;27(3):491-499
pubmed: 28100584
mBio. 2013 Aug 06;4(4):
pubmed: 23919993
PLoS One. 2014 Nov 19;9(11):e112963
pubmed: 25409509
J Virol. 2013 Apr;87(7):3885-902
pubmed: 23365422
JCI Insight. 2021 Aug 23;6(16):
pubmed: 34237028
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
Cell Host Microbe. 2021 Apr 14;29(4):508-515
pubmed: 33789086
Nat Immunol. 2020 Nov;21(11):1327-1335
pubmed: 32839612